Background: In newly diagnosed multiple myeloma (NDMM), autologous stem cell
depth of response and maintenance therapy to achieve long-term disease control. [6] [7] [8] Consolidation strategies with novel agents incorporated treatment dose for 2-6 cycles' post-transplant single agent or combination therapy. A handful of studies has demonstrated that post-transplant consolidation with both bortezomib alone or bortezomib combination therapy with thalidomide and dexamethasone (VTD) resulted in improved progression-free survival (PFS); however, a translation to an improved overall survival (OS) has yet to be established. [9] [10] [11] [12] Moreover, the overall cumulative toxicity of thalidomide and the potential consequent treatment discontinuation remains a limitation in these studies.
On the other hand, studies that used lenalidomide (LEN) demonstrated that it is better tolerated than thalidomide with a more favourable toxicity profile, even though no formal comparison between the 2 immunomodulatory drugs has been undertaken. 7, 13, 14 In a phase II study, post-transplant consolidation with LEN, bortezomib and dexamethasone (RVD) combined with LEN maintenance in NDMM resulted in a 3-year PFS of 77% and OS of 100%.
14 Later on, a phase III randomised control trial (RCT) demonstrated that RVD consolidation followed by LEN maintenance after ASCT resulted in a 3-year PFS and OS rates of 61% and 88%, respectively. 1 In addition, Overall, LEN maintenance following ASCT appears to induce significant benefits in PFS with potential benefits in OS. However, these
benefits have yet to be confirmed with consolidation therapy. In this systematic review, we sought to compare the time to disease progression (PFS), overall response rate and safety of consolidation plus LEN maintenance vs LEN maintenance alone following a single ASCT in NDMM patients.
| METHODS

| Data sources and search strategy
We conducted a systematic literature search to identify potential stud- Table S1 .
Two reviewers (FA and ML) selected potential studies for inclusion.
Discrepancies were resolved by consensus.
| Eligibility criteria
Using a structured question format to aid our literature search strategy, we reviewed all potentially relevant abstracts to ensure that they satisfied our criteria: (i) phase III RCTs or phase II studies that included adult patients with NDMM treated with ASCT; (ii) participants received LEN maintenance following transplant with or without post-transplant consolidation; (iii) at least one or more of the primary or secondary outcomes were reported. Studies were excluded if the study was phase I, if patients had consolidation with tandem transplant, or if duplicated data were reported.
| Outcome measures
The primary outcome measures were the efficacy endpoints includ- With regard to heterogeneity in design among studies, a subgroup analysis of phase III RCTs vs phase II studies was planned. To overcome any treatment-related bias with respect to efficacy and safety of the various regimens utilised, we also planned to assess PFS, OS and response rates according to consolidation/induction therapy used in the clinical trials.
| Data collection process
Initially, a broad screening was conducted according to title.
Subsequently, two reviewers (FA and ML) independently applied the inclusion criteria to the identified articles from the initial search strategy, and all potentially relevant articles were reviewed in full length.
The methodological quality of eligible studies was performed independently by the two reviewers and the required information was extracted and documented in a spread sheet (Microsoft Excel, 2010).
The risk of bias of the selected RCTs was assessed according to risk of bias assessment tool from the Cochrane Handbook (http://www.
cochrane.org/resources/handbook). The methodological quality of the single arm phase II studies was assessed according to NewcastleOttawa Quality Assessment Scale for prospective cohort studies.
Disagreements were resolved by consensus.
| Statistical analysis
We obtained proportions for all reported outcomes. A metaanalysis of simple proportions was conducted to obtain pooled estimates of events using fixed and random effects models. This methodology allows obtaining weighted estimates of proportions for different outcomes with the weights estimated according to Laird and Mosteller. 17, 18 Relative risks (RRs) were calculated using 2 × 2 contingency tables, and 95% confidence intervals (CIs) were calculated using Taylor series. Calculations were performed using Microsoft 
| RESULTS
| Search strategy
Details of the literature search strategy are presented in Figure 1 . In total, 1459 citations were identified by our systematic search of the literature, including 257 duplicates. After abstracts review, 56 articles fulfilled our inclusion criteria and were reviewed in full. Of those, 12
did not incorporate LEN maintenance in their treatment regimen; 12 were duplicates; 11 did not report on the outcome of interest; 5 did not include ASCT; 1 assessed consolidation after tandem ASCT; and the full text was not available in the remaining 1. The corresponding authors of 5 articles with missing information were contacted, 2 responded and were able to provide the required information. 13, 19 Updated results of 5 included RCTs were found, and the most comprehensive data were included in our analysis. 2, 15, [20] [21] [22] In the end, we included 14 studies (7 full-text articles and 7 abstracts) published between 2010 and 2017. The 7 included abstracts did provide enough information to be considered appropriate for inclusion in our review.
There were no discrepancies between the 2 reviewers with regard to study eligibility.
| Description of studies
Fourteen studies with a total of 2275 participants with NDMM treated with induction therapy, high-dose melphalan and ASCT, followed by LEN maintenance with or without consolidation therapy, were included. The median age of participants ranged between 55
and 67 years of age. Baseline characteristics of included studies are summarised in Table S2 27 The induction treatments in the remaining studies are detailed in Table   F 
| Studies design
Fourteen studies, including 8 phase III RCTs and 6 phase II studies, were included.
Phase III RCT
Of the 8 phase III RCTs, 5 were open label studies 13, 16, 20, 23, 24 and 2 were double blinded RCTs, 2, 15 and no data were available for the remaining study. 22 The intervention and comparator arms were related to transplant vs no transplant in 3 studies, 13, 20, 22 LEN maintenance vs no maintenance in 3 2,15,23 ; and 1 study compared LEN maintenance vs no maintenance in both transplant and no transplant patients' groups. 16 The StaMINA trial was a phase III RCT that randomised NDMM patients following transplant into 3 arms: RVD consolidation (n = 254); or tandem ASCT consolidation (n = 247); or no consolidation (n = 257). All patients received LEN maintenance. 24 In fact, the StaMINA trial was the only study in which the intervention and comparator were related to consolidation plus LEN maintenance vs LEN maintenance alone (and vs tandem transplant with LEN maintenance). 24 In our review, we are not including the information regarding patients that underwent tandem ASCT as a consolidation mode.
Phase II studies
Of the 6 phase II studies, 4 were single arm. 14, 21, 27, 28 Of those, consolidation treatment followed by LEN maintenance was assessed in 3. 14, 21, 27 One study evaluated LEN maintenance alone. 28 In the re- 
| Risk of bias
cochrane.org/resources/handbook). The methodological quality of the selected single arm phase II studies was assessed according to Newcastle-Ottawa Quality Assessment Scale. Overall, the risk of bias for the included RCT was low. However, it is noteworthy to state that the adequate sequence generation, allocation concealment and blinding of participants were unclear in most RCTs ( to representativeness of exposed cohort and adequacy of followup (Table 2) . Nevertheless, overall, the missing information in the 7 included abstracts hampers proper assessment of studies' quality.
| Clinical results
Of the total 2275 participants, 2 groups were identified according to post-transplant treatment: (i) consolidation plus lenalidomide maintenance (CON+LEN) group in 7 studies (n = 1102) (48%); (ii) LEN maintenance alone (LEN alone) group in 8 studies (n = 1173) (52%). The
StaMINA trial assessed both treatment regimens in 2 separate arms, so it was included in both groups. 24 
| Disease progression and overall survival
Most of the included studies reported on PFS and OS at 3-4 years of Overall, PFS and OS rates were similar with both random effect and fixed effect estimates in the 2 treatment groups, as shown in To overcome the induction/consolidation treatment bias, we attempted to assess the effect of each treatment regimens used on the outcomes of our study. A separate subgroup analysis was conducted within the CON+LEN group according to consolidation treatment used.
Only one study with KRD consolidation was not included in this subgroup analysis due to insufficient data reported. 27 We were able to assess two We planned on evaluation of induction treatments used on PFS and OS. However, the variability of the treatments used in studies precluded us from performing this analysis.
| Response rate
Overall, the depth of response varied. After transplant, the rate of VGPR or better ranged from 29% to 88% in all included studies. After consolidation therapy, this rate was found to be higher, between 69% and 93%. In our analysis, we opted to assess the depth of re- of CR rates are shown in We planned to evaluate the impact of different induction/ consolidation treatments on the response rates. However, data were insufficient. Similarly, we were unable to perform a subgroup analysis regarding the impact of those treatments strategies on MRD negativity.
| Toxicity
Data on treatment emergent adverse events were extremely limited, and we were only able to pool data on secondary primary malignancy (SPM). Due to insufficient data, we were unable to report on solid and haematological malignancies separately. Herein, we present the total SPM rate including both solid and haematological malignancies. Of the total 2275 participants, there were 940 (41.3%) evaluable participants in the CON+LEN group and 532 (23%) in LEN alone group for SPM reporting. We found that, at 3-4 years of follow-up, the SPM rate was 7% (95% CI: 6.97-7.03) in CON+LEN group and 6% (95% CI: 5.98- However, only 1 of these studies used post-transplant consolidation. 2 The question of whether to administer consolidation therapy following transplant is needed and it is still controversial.
We conducted a systematic review of phase III RCTs and phase II studies to compare PFS, OS and overall response rates, along with safety of consolidation plus LEN maintenance vs LEN maintenance alone following ASCT in NDMM patients. In total, we included 14 studies with 2275 participants. We found that the depth of response (VGPR or better) was significantly higher in the CON+LEN group com- T A B L E 4 Subgroup analysis within CON+LEN group according to consolidation therapy: pooled rates of progression-free survival (PFS) and overall survival (OS) Our findings are in keeping with the results of the StaMINA trial. 24 This study demonstrated that the addition of RVD consolidation or a second autologous stem cell transplant did not provide a superior outcome to a single ASCT followed immediately by LEN maintenance.
At 3 years of follow-up of the StaMINA participants, the PFS was 57% (95% CI: 50-63%), and estimated OS was 86% (95% CI: 80-90%) for those on RVD consolidation followed by LEN maintenance, whereas with LEN maintenance alone, the PFS was 52% (95% CI: MRD-negative patients. 30 In our study, due to insufficient data, we were unable to analyse MRD status with consolidation.
SPM is one of the most feared side effects of lenalidomide. In our systematic review, we were able to identify a similar rate between CON+LEN (6%) and LEN alone (7%) groups. Our results are comparable to the literature. 31 Palumbo et al conducted a meta-analysis of phase III trials assessing SPM with lenalidomide as first-line therapy in NDMM. 31 The reported cumulative incidence of all SPM was 4%-7% at 3-5 years. Our rates of SPM were higher, and this can be potentially explained by the prolonged exposure to LEN during maintenance therapy, compared to the duration of induction.
Our systematic review has several strengths and potential limitations that should be addressed. First, we opted to conduct our analysis with simple proportions of pooled estimates using fixed and random effects models. This methodology allows obtaining weighted estimates of proportions for different outcomes. The total number of participants (n = 2275) was large enough to draw meaningful conclusions. In addition, the number of participants in each treatment group was comparable (n = 1102 in CON+LEN and n = 1173 in LEN alone).
However, even though most of the studies were considered to have a good methodological quality, many RCTs lacked information on randomisation procedures, such as allocation concealment and blinding, despite the fact that they were published in high impact journals. This raises the important need for investigators and publishers to pay more detailed attention to the reporting of methodological procedures.
The conditioning regimen with high-dose melphalan was uniform in all studies. However, we acknowledge the fact that the included studies evaluated different induction and consolidation treatment strategies. When we attempted to perform subgroup analyses ac- Furthermore, we were only able to report our outcomes for a relatively short follow-up period (3-4 years) and data on the impact of consolidation in long-term PFS and OS are still immature. Our ability to evaluate outcomes in high-risk population and toxicity parameters was limited by the lacking of reporting. Despite the presence of a considerable number of high-risk patients in many studies, this number in most of the cases was unevaluable for our outcome of interest. Therefore, we were unable to perform a formal comparison between the high risk and the standard risk patients in our analysis. Furthermore, with regard to the significant impact on the depth of response with consolidation therapy, lack of data on MRD status precluded us from confirming this finding, as MRD status is probably one of the most important features contributing to the link between the depth of response and long-term outcomes. 30 Finally, we were unable to report pooled estimates of solid and haematological malignancies separately due to insufficient data.
| CONCLUSION
We acknowledge that the data we are presenting in this systematic review are still immature, as the included studies report on 3 to 
